HeartSciences annual revenue
2022
2023
2024
2025
2026
HeartSciences Revenue Growth & History (HSCS)
HeartSciences reported $4,319 in revenue for fiscal 2026, a decrease of 0.71% from the previous fiscal year.
View full HeartSciences company overviewHeartSciences annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $4,319 | −$31 | −0.71% |
| 2025 | 2025-04-30 | $4,350 | −$14,250 | −76.61% |
| 2024 | 2024-04-30 | $18,600 | $13,450 | +261.17% |
| 2023 | 2023-04-30 | $5,150 | −$9,223 | −64.17% |
| 2022 | 2022-04-30 | $14,373 | — | — |
HeartSciences quarterly revenue
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q2.24
Q3.24
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $0 | −$4,350 | −100.00% |
| Q3 2026 | 2026-01-31 | $0 | $0 | — |
| Q2 2026 | 2025-10-31 | $2,419 | — | — |
| Q1 2026 | 2025-07-31 | $1,900 | — | — |
| Q4 2025 | 2025-04-30 | $4,350 | — | — |
| Q3 2025 | 2025-01-31 | $0 | −$14,700 | −100.00% |
| Q3 2024 | 2024-01-31 | $14,700 | $12,750 | +653.85% |
| Q2 2024 | 2023-10-31 | $3,900 | $3,900 | — |
| Q4 2023 | 2023-04-30 | $0 | −$4,149 | −100.00% |
| Q3 2023 | 2023-01-31 | $1,950 | −$790 | −28.83% |
| Q2 2023 | 2022-10-31 | $0 | $0 | — |
| Q1 2023 | 2022-07-31 | $3,200 | −$4,284 | −57.24% |
| Q4 2022 | 2022-04-30 | $4,149 | — | — |
| Q3 2022 | 2022-01-31 | $2,740 | — | — |
| Q2 2022 | 2021-10-31 | $0 | — | — |
| Q1 2022 | 2021-07-31 | $7,484 | — | — |
HeartSciences revenue growth trends
HeartSciences's latest reported quarter, Q4 2026, generated $0 in revenue, a decrease of 100.00% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review HeartSciences source filings ↗